Navigation Links
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
Date:2/29/2008

- Otsuka-sponsored Study Evaluated Use of ABILIFY In This Patient

Population -

TOKYO and PRINCETON, N.J., Feb. 29 /PRNewswire/ -- Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for ABILIFY(R) (aripiprazole) for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder, with or without psychotic features in pediatric patients (10 to 17 years old). ABILIFY has been approved for the acute and maintenance treatment of manic and mixed episodes associated with Bipolar I Disorder with or without psychotic features in adults since September 2004 and March 2005, respectively.

"Pediatric bipolar illness is a serious condition," said Christoph Correll, M.D., Medical Director, Recognition and Prevention Program, The Zucker Hillside Hospital and Assistant Professor of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Glen Oaks, New York. "The availability of an additional treatment option that can help guide decisions in managing Bipolar I Disorder in children and adolescents is welcome news."

The approval is based on results from a four-week, multicenter, randomized, double-blind, placebo-controlled study in pediatric patients (10 to 17 years old) with Bipolar I Disorder that demonstrated efficacy with ABILIFY compared to placebo on the primary efficacy endpoint, mean change from baseline to Week 4 on the Young-Mania Rating Scale (Y-MRS) Total Score.

"We are pleased that the FDA has approved ABILIFY to treat pediatric patients aged 10 to 17 years suffering from Bipolar I Disorder," said Taro Iwamoto, Ph
'/>"/>

SOURCE Otsuka Pharmaceutical Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
2. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
3. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
4. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
5. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
6. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
7. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
8. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
9. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
10. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...EW YORK, July 24 /- MacroCh...nounced results of a Phase 2 clinical trial,involv...i-center,open-label efficacy and safety study of ...tment of onychomycosis (nail fungus). The composit...lete cure" defined as,negative mycology (negative ...
(Date:7/23/2008)...tudy results pending publication in July print edi...vailable on Web, INDIANAPOLIS, July 23 /PRNewswir...aluating the use of N-terminal pro-B-type natriure...ue of NT-proBNP for risk,stratification in predict...AE) in patients treated with non-steroidal anti-in...
(Date:7/23/2008)...OSTON, July 23 /- FluoroPharma Inc., ...g agents for the Positron Emission Tomography,(PET...FPET, its novel,Fluorine-18 labeled tracer for myo... second cardiovascular product to complete Phase I...ent, designed to assess the blood flow in the,hear...
(Date:7/23/2008)...EATTLE, July 23 /- Dendreon... it expects the Independent Data,Monitoring Commit...nalysis,of overall survival relating to the Compan...noCarcinoma Treatment, also known as D9902B) clini...is the Company,s investigational,active cellular i...
Breaking Medicine Technology:MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 3MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 5Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Largest Ever Regional AIDS Conference to Review Epidemic Status and Changing Challenges in the Response 18253 1Largest Ever Regional AIDS Conference to Review Epidemic Status and Changing Challenges in the Response 18253 2Largest Ever Regional AIDS Conference to Review Epidemic Status and Changing Challenges in the Response 18253 3Largest Ever Regional AIDS Conference to Review Epidemic Status and Changing Challenges in the Response 18253 4Stinger Systems Inc Settles With the SEC 3158 1Male seahorses are natures Mr Mom Texas A 26M researchers say 3155 1Male seahorses are natures Mr Mom Texas A 26M researchers say 3155 2Male seahorses are natures Mr Mom Texas A 26M researchers say 3155 3Male seahorses are natures Mr Mom Texas A 26M researchers say 3155 4Masimo to Present at Deutsche Bank 33rd Annual Health Care Conference 5057 1Masimo to Present at Deutsche Bank 33rd Annual Health Care Conference 5057 2
...ented at 2007 APA Meeting Also Showed No,Significa...COLLEGEVILLE, Pa., May 21, 2007 /PRNewswire-FirstC... - one examining the,effect of desvenlafaxine succ... symptoms associated with major depressive disorde...hat examined the,effect of desvenlafaxine succinat...
...7 Percent Reduction in Risk of Hospitalization,fro...PARK, Ill., May 22, 2007 /PRNewswire-FirstCall/ --...alysis of a pivotal study,presented at the Digesti... showing patients with moderate to severely active...b) maintenance,therapy were almost 60 percent less...
Other Medicine Technology:Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 2Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 3Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 4Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 5Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 6New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 2New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 3New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 4New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 5New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 6New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 7
(Date:7/25/2008)...Robert J. Reilly, Joins Aethon Team, PITTSBURGH, ...ethon.com ), the leading developer of mobile robot...ounced that Robert J. Reilly has,joined the compan...cer., Reilly, who was most recently Vice Presiden...ecialty Pharmacy Division, brings more than 30,yea...
(Date:7/25/2008)...an cause immune system changes , , FRIDA...linking gastroesophageal reflux disease (GERD) and...ical Center researchers. , An association betwe..., and since then studies have shown that between 5...xperience GERD symptoms. But the actual link betwe...
(Date:7/25/2008)...mation Association (DIA) and the Food and Drug Adm...iative (CPI) on the Move: Complexities and Challen...cal Path Transporter Workshop (October 2-3; North ... PA (PRWEB) July 25, 2005-- The http://www.diahom...he Food and Drug Administration (FDA) will host th...
(Date:7/24/2008)...wswire/ -- Speaker Nancy Pelosi,released the follo...Lantos,and Henry J. Hyde Global Leadership Against...on Act of 2008. The bill, which passed the Senate ... of 303 to 115 and will now go,the President for h...historic vote to pass landmark legislation to,reau...
Breaking Medicine News(10 mins):Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:People With GERD More Likely to Develop Asthma 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 3Health News:Pelosi Statement on House Passage of Global AIDS Legislation 2
... over have one more reason to raise a toast- a for...s on how you // can pep-up your spirits and reli...Wine Studies at Coventry University, and author of...worthwhile to recall the laws while popping open a...
...ector, K. Sellamuthu, has ordered distribution of ...g places // such as tea stalls, hair cutting sal... as these are the places where large number of pub...was initiated by the Tamilnadu State AIDS Control ...
... delayed to a great extent by taking walks thrice ...ood flow // and leg pain, according to a recent ... be improved through the exercise. As a part of th... of 417 men and women by measuring the distance th...
...Science organization reveal that the detox tablets...The body // has the capacity to take what is esse...he substances that are ingested are not harmful an...he detox industry that includes everything from di...
Other Medicine News:
... is recommended for separations of DNA fragments <...at are easy to handle, and remains flexible even a...f cracking or breaking. Certified PCR agarose, unl...ilar sieving properties, is a standard gelling tem...
The PK TP System utilizes fixed chicken erythrocytes sensitized with components of the pathogenic T. pallidum (Nichols Strain) to perform a qualitative screening of Treponema pallidum in human serum
Agarose-HR™ High Resolution - Efficiently separates DNA fragments from 50 to 1000 bp. It is useful for sizing PCR fragments, small DNA fragments generated by restriction enzyme digestion, and d
...ning donors on the PK7200 Automated Microplate Sys...d to a gelatin particle for the detection of cytom...f the CMV assay as compared to EIA measures 99.8% ...cle as the carrier provides excellent lot-to-lot c...
Medicine Products: